Regulus Therapeutics upped the dosage of its microRNA hepatitis C therapy RG-101 in a small study and gathered evidence of a bigger impact on patients' viral loads. But investigators also added new evidence that the treatment was far less durable than the new therapies hitting the marketplace, sending a shiver through the market this morning.
Regulus Therapeutics, at work on a microRNA approach to hepatitis C, watched its shares skyrocket on positive early data for its lead candidate, which significantly reduced viral loads with a single dose.
Regulus Therapeutics has partnered up with Biogen Idec to identify microRNA biomarkers in the blood of patients with multiple sclerosis, and the California biotech has charted some progress, pocketing a milestone payment and moving toward companion diagnostic development.
Regulus Therapeutics, a biotech using microRNA as a target for drug delivery, raised nearly $49 million through a public offering completed Tuesday, up from an anticipated $43 million.
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant (email | Twitter) and we will feature it...
It may not have been pretty, but Regulus Therapeutics raised close to $81 million from its recent IPO and some related transactions.
It may not have been pretty, but Regulus Therapeutics ($RGLS) raised close to $81 million from its recent IPO and some related transactions. And they did it with a big assist from some major league partners in the biopharma industry.
After taking a beating in previous years, biotech has been hot sector on Wall Street this year. The Nasdaq Biotech Index has shot up 30% this year compared with 15% growth in the broader market. And the fact that this year's total number of biotech IPOs already matches that of 2011 indicates that there could be a growing appetite for these types of investments. But there's no indication that we're on the verge of, or will ever, return to the go-go years of the 1990s when biotechs more easily went public at lofty values. Here's the full report >>
Regulus Therapeutics capped a busy week of deal-making with a proposed initial public offering of $57.5 million, which the biotech would use in part to fund work on its pipeline of microRNA drugs now in pre-clinical development for cancer, hepatitis C, cardiovascular and fibrotic diseases.
Regulus Therapeutics has signed a deal to lend its microRNA knowhow to Biogen Idec, looking to develop diagnostics for multiple sclerosis.